First Trust Bloomberg R&D Leaders ETF (RND)

The First Trust Bloomberg R&D Leaders ETF (RND) is an actively managed fund that invests in U.S. companies whose research and development spending, relative to their sales, is highest in the market — the idea being that firms willing to pour money into innovation tend to outperform peers and drive long-term wealth creation.

RND begins from a simple observation: companies that invest heavily in R&D relative to their size are making a conscious bet on the future. They are not squeezing short-term profits; they are funding the inventions, processes, and products that will differentiate them for years to come. Apple’s silicon design, Merck’s drug pipeline, Tesla’s battery research, Microsoft’s cloud infrastructure — these are built on years of R&D spending that did not produce immediate returns. RND hunts for publicly traded companies with similar commitment to innovation and bets that such commitment will be rewarded.

The R&D intensity screen

The fund uses a quantitative filter to identify R&D leaders. Rather than holding all 500 large-cap stocks, it screens the universe for those spending the highest percentage of revenue on research and development. This is an intensity ratio, not an absolute dollar amount. A small biotech company that spends 30 percent of revenue on drug discovery will rank higher than a major pharmaceutical firm spending 10 percent, even if the large firm spends more dollars in total. The screen is deliberately designed to capture the firms most committed to innovation at any scale.

This approach filters out the mature, cash-machine businesses — consumer staples, utilities, established financials — that do little R&D. It concentrates instead in sectors where innovation is the lifeblood: technology, healthcare, industrials, and consumer discretionary companies betting on the next generation of products. The result is a portfolio biased toward companies either young enough that innovation is existential, or mature enough to afford serious R&D but still willing to fund it aggressively.

Active management and rebalancing

Unlike a pure passive index fund, RND relies on active management. A portfolio manager uses the R&D intensity metric as a starting point, then applies judgment to construct the portfolio — deciding how many positions to hold, what the target weights should be, and whether to trim or avoid companies that rank high on R&D but have other red flags (weak margins, deteriorating competitive position, excessive debt). This adds a layer of human oversight that a mechanical screen alone would not provide, and it justifies the higher expense ratio typical of actively managed funds.

The fund rebalances regularly, selling positions that have risen sharply in value and no longer offer compelling risk-reward, and buying into those that have fallen but still show strong R&D commitment. This disciplined rebalancing forces a degree of buy-low, sell-high behavior — though in volatile markets, it also means sometimes selling winners too early or buying losers that deserve to stay cheap.

Sector and stock concentration

Because R&D-intensive industries cluster in certain sectors, RND’s portfolio naturally skews toward technology, pharmaceuticals and biotechnology, and capital-goods manufacturing. Technology companies — software, semiconductors, cloud services, digital infrastructure — are typically the largest holdings, because the sector as a whole is built on continuous innovation. Healthcare and biotech appear heavily, given the enormous R&D spend required to bring new drugs to market. Smaller portions flow into aerospace and defense, autos (particularly electric vehicle makers), and specialty industrials.

This concentration is a feature and a risk. The feature is that RND offers a focused bet on innovation-driven growth in the sectors where innovation matters most. The risk is that a downturn specific to technology — a credit crunch that starves startups, a shift in government spending, a loss of venture funding — will hit RND harder than a diversified broad-market fund. An investor is not just buying U.S. equities; they are buying a particular view on where the economy is heading: that innovation will drive outperformance, and that tech-heavy sectors will lead.

The cyclical nature of the bet

R&D-intensive stocks tend to outperform in periods of rising growth expectations and falling interest rates, because their earnings are far in the future and are therefore worth more when discounting future cash flows at lower rates. In periods of economic slowdown or rising rates, markets often reprrice these companies downward as investors flee growth bets and chase immediate earnings. This makes RND a somewhat cyclical fund, despite its focus on long-term innovation. An investor holding it through a sharp interest-rate shock or a recession may experience a significant decline, even if the underlying companies continue investing in R&D and remain healthy.

Conversely, in a long period of low rates and steady economic expansion — where investors are confident enough to fund future innovation — RND tends to shine, because the companies it holds are best positioned to capture growth. Knowing your own tolerance for these cycles is crucial. RND is not a defensive fund; it is a growth bet, and growth bets swing wider than the market during downturns.

How to research RND

Start by reviewing the fund’s holdings and comparing them to your own views on which sectors and companies are best positioned to innovate successfully. The portfolio typically includes between 40 and 80 stocks; you can find the most recent list on the fund’s website or financial data aggregators.

Next, examine the fund’s track record relative to the broader market and to other innovation-focused or growth-oriented ETFs. Over a full market cycle — including bull runs and downturns — has RND’s bet on R&D intensity actually paid off? Or has it underperformed, suggesting that high R&D spending does not reliably predict outperformance?

Finally, consider whether the sector concentration is one you are comfortable with. If you believe technology and biotech will lead the economy for the next decade, and you want to overweight innovation, RND offers a vehicle for that view. If you prefer broad diversification or worry about tech concentration, a different fund may suit you better. As always, the prospectus and fact sheet are the official sources; publications and commentary help contextualize, but the fund documents are the bedrock.